To compare the proteomic profiles of primary uveal melanomas, with and without loss of chromosome 3.
U veal melanoma causes metastatic disease in approximately 50% of all patients, despite successful treatment of the primary intraocular tumor. 1 Metastatic disease usually involves the liver and is invariably fatal, typically within a year of the onset of symptoms. 2, 3 Uveal melanomas can essentially be subtyped into low-and high-grade metastatic risk groups, according to their clinical, histologic and genotypic features. [2] [3] [4] [5] [6] Knowledge of a particular tumor's characteristics allows for a more accurate prediction of metastasis in the individual patient and aids treatment and management decisions. 2, 3 Although a large amount of information is available with regard to the molecular biological differences of low-and high-grade uveal melanomas, little is known about the corresponding protein complement of the genome (proteomics) in these melanoma subgroups. To date, proteomic analysis has been conducted on uveal melanoma cell lines, [7] [8] [9] serum, 10 and aqueous humor 11 of patients with uveal melanoma. These investigations revealed overexpression and underexpression of some proteins; however, no correlation was made with the cytogenetic status of the tumor cells.
The purpose of our study was, therefore, to determine whether the proteomic profiles of monosomy 3 uveal melanomas differed significantly from those of disomy 3 tumors and, if so, whether such differences identified possible biomarkers of the high-grade uveal melanomas.
METHODS
The study was approved by the local committee of the National Research Ethics Service and informed consent was obtained from all patients. The research adhered to the tenets of the Declaration of Helsinki.
Proteomic Analysis
Seven uveal melanomas were selected for proteomic analysis. These frozen tumor samples had been taken from uveal melanomas treated by local resection or enucleation in 2005 and had been selected on the basis of cytogenetic analysis for chromosome 3 routinely performed by fluorescence in situ hybridization (FISH) at this time. 2 The histomorphologic features of these seven uveal melanomas were noted after routine fixation, embedding in paraffin, and staining of sections, using hematoxylin and eosin (H&E) and periodic acid Schiff (PAS).
Triton X-100, 2% (vol/vol) immobilized pH gradient (IPG) buffer (pH 3-10NL), and 2% (wt/vol) dithiothreitol (DTT). The protein samples were stored at Ϫ80°C. The total protein content in each melanoma sample was assayed (Non-interfering Protein Assay; Calbiochem-Merck Chemicals, Beeston, UK). [vol/vol] IPG buffer), using a dry strip tray (Immobiline DryStrip Reswelling Tray; Amersham Pharmacia Biotech). IEF was performed on an electrophoresis unit (Multiphor II; PerkinElmer Windsor, UK) at 500 V for 0.01 hour, 500 V for 5 hours, 3500 V for 5 hours, and 3500 V for 9.5 hours in a gradient mode at 17°C (MultiTemp III Thermostatic Circulator; GE Healthcare Life Sciences, Buckinghamshire, UK). Before two-dimensional SDS-PAGE, the IPG strip was equilibrated twice: first for 10 minutes under gentle agitation in 20 mL of equilibration solution containing 0.6% (wt/vol) Tris-HCl (pH 6.8), 6 M urea, 30% (vol/vol) glycerol, 1% (wt/vol) SDS, and 0.05% (wt/vol) DTT; and second in 4.5% (wt/vol) iodoacetamide and bromophenol blue. For the second dimension, the equilibrated IPG strip was transferred to a polyacrylamide gel. Electrophoresis was then performed vertically at a maximum voltage of 50 V, 5 mA for approximately 20 hours on equipment designed and previously described by Vorum et al.
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Silver Staining. Gels were visualized by silver staining optimized for high-sensitivity protein identification by mass spectrometry.
14 Briefly, individual gels were fixed in 50% (vol/vol) ethanol, 12% (vol/vol) acetic acid, and 0.0185% (vol/vol) formaldehyde overnight. After the gels were washed three times for 20 minutes in 35% (vol/vol) ethanol and pretreated for 1 minute in 0.02% (wt/vol) Na 2 S 2 O 3 ;5H 2 O, they were rinsed in water and stained in 0.2% (wt/vol) AgNO 3 and 0.028% (vol/vol) formaldehyde for 20 minutes. Further rinsing with water was performed before development in 6% (wt/vol) Na 2 CO 3 and 0.0185% (vol/vol) formaldehyde, 0.0004% (wt/vol) Na 2 S 2 O 3 ;5H 2 O, for approximately 3 minutes. Finally, development was arrested in a fixative solution of 40% (vol/vol) ethanol, 12% (vol/vol) acetic acid.
Image Analysis. Silver-stained gels were scanned with a densitometer (GS-710 Calibrated Imaging Densitometer; Bio-Rad, Hemel Hempstead, UK). The peptide spots were analyzed by software (PDQuest software; Bio-Rad) that designated a volume to each spot proportional to the amount of protein. All well-separated and clearly focused spots that were 1.5-fold (Student's t-test P Ͻ 0.05) differentially expressed between the disomy 3 and monosomy 3 uveal melanomas were selected for identification by liquid chromatographytandem mass spectrometry.
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Protein Identification. The proteins were excised from the gels and subjected to in-gel digestion. The peptide samples were analyzed by LC-MS/MS essentially as described. 12 In short, digested peptides were separated on an inert nano liquid chromatography system (LC Packings, San Francisco, CA) connected to a mass spectrometer (Q-Tof Premier; Waters, Milford, MA), spectra were obtained (MassLynx 4 SP4; Waters), and raw data were processed (ProteinLynx GlobalServer 2.1; Waters). The processed data were used to search the total part of the Swiss-Prot database (release 52.4, 265,950 sequences; http://www.expasy.org; provided in the public domain by Swiss Institute of Bioinformatics, Geneva, Switzerland) using the online version of the Mascot MS/MS Ion Search facility (http://www.matrixscience-.com/ available commercially from Matrix Science, Ltd., London, UK). The search was performed with doubly and triply charged ions with two missed cleavages, a peptide tolerance of 50 ppm, one variable modification, carbamidomethyl-C, and an MS/MS tolerance of 0.05 Da. Contaminating peptides, such as keratins and trypsin, cross-contaminating peptides from previous samples, and peptides originating from different sources such as BSA, were disregarded. At least one bold red peptide was required in the search. The scores of the protein hits were recorded and are reported herein. Individual peptide ion scores higher than 36 indicate identity or extensive homology, giving a less than 5% probability that the observed match was a random event.
Western Blot Analysis
Samples were loaded and run on 10% to 20% gradient Tris-Glycine polyacrylamide gels (Novex; Invitrogen Corp.; Paisley, Scotland, UK). After transfer by electroelution to nitrocellulose membranes (Hybond-C Extra; Amersham, UK), the blots were blocked with 5% milk in 80 mM Na 2 HPO 4 , 20 mM NaH 2 PO 4 , 100 mM NaCl, and 0.1% Tween 20 (PBS-T; pH 7.5) for 1 hour and incubated overnight at 4°C with the appropriate primary antibodies ( Table 1 ). The labeling was visualized with horseradish peroxidase (HRP)-conjugated secondary antibodies (P0217, P0449, or P0260; DakoCytomation, Glostrup, Denmark, and ab16349-250; Abcam, Cambridge, UK) by enhanced chemiluminescence (GE Healthcare). In an effort to conserve tissue samples, some blots were reprobed after treatment with Western blot stripping buffer according to the manufacturer's protocol (Restore; Pierce Biotechnology Inc., Rockford, IL).
Immunohistochemistry
Antigens identified as being significantly differentially expressed between monosomy 3 and disomy 3 tumors in the proteomic studies were further investigated by immunohistochemistry applied to an independent cohort of 41 uveal melanomas. These 41 tumors were selected on the basis of their chromosome 3 status, as determined for prognostication purposes by MLPA 4 in a fresh biopsy taken directly after enucleation or tumor excision between 2006 and 2008.
After conventional staining of these 41 uveal melanomas with H&E and PAS, immunohistochemistry was performed on 4-m sections made from the corresponding formalin-fixed, paraffin-embedded (FFPE) tissue blocks. Sections were dewaxed, rehydrated, and endogenous peroxidase blocked with H 2 O 2 in methanol. To detect HSP-27, we also subjected the slides to heat-induced epitope retrieval (pH 7.0) before incubation with the appropriate antibody. After they were rinsed in running water, slides were loaded onto an autostainer (DakoCytomation) and washed with phosphate-buffered saline (PBS). The sections were incubated with primary antibody for 40 minutes at room temperature (RT): mouse antihuman HSP-27 antibody, diluted 1:100 (Novocastra, Newcastle, UK), and mouse anti-human vimentin antibody, 1 g/mL (DakoCytomation). Bound antibody was detected with an HRP system (Advance; DakoCytomation) according to the manufacturer's instructions. Peroxidase was visualized with an AEC substrate kit (Vector Laboratories Ltd, Peterborough, UK), and the sections were counterstained with Mayer's hematoxylin and mounted in aqueous medium (Aquatex; Merck Chemicals, Ltd., Nottingham, UK). Negative control experiments were performed by replacing the primary antibody with mouse isotype control antibody. Normal human skin and tonsil were used as positive control tissues for HSP-27 and vimentin antibodies, respectively.
The percentages of melanoma cells staining for HSP-27 and vimentin were evaluated by two independent observers who were unaware of the chromosome 3 status. These percentages were scored as follows: 0% tumor cells positive (score 0), 1% to 24% tumor cells positive (score 1), 25% to 49% tumor cells positive (score 2), 50% to 74% tumor cells positive (score 3), and 75% to 100% tumor cells positive (score 4). The intensity of cellular staining was also scored as none (0), weak (1), moderate (2), or strong (3). A combined score was thus obtained by multiplying the two scores, as previously described in other tumors, 15 giving a possible maximum score of 12.
Multiplex Ligation-Dependent Probe Amplification (MLPA)
The genomic abnormalities of the independent cohort of 41 uveal melanomas were determined with MLPA, as described previously. 
Statistical Analysis
Differences in the protein expression levels for HSP-27 and vimentin were examined with a Student's t-test between the uveal melanoma subgroups (i.e., monosomy 3 versus disomy 3). This test was also used for any correlations with histomorphologic features (e.g., cell type and presence or absence of closed loops). Correlations between the protein expression levels for HSP-27 or vimentin and age at primary diagnosis, largest basal diameter (LBD), tumor height, and mitotic frequency were determined with the bivariate Spearman's correlation (all statistical analysis by SPSS, ver.11.0; SPSS Science, Chicago, IL).
RESULTS

Differential Protein Expression According to the Presence or Absence of Monosomy 3
The proteomic profiles of three disomy 3 uveal melanomas were compared with those of four monosomy 3 tumors. The clinical, histopathologic, and cytogenetic features of these tumors are summarized in Table 2 . Two protein spots were overexpressed in the disomy 3 melanomas compared with the monosomy 3 tumors, whereas two spots were underexpressed (Fig. 1) . In four spots, tandem mass spectrometry identified nine proteins, as indicated in Table 3 . Western blot analysis of the protein extracts showed significant differences for HSP-27 and vimentin but not pyruvate dehydrogenase ␤ (PDHB; Fig. 2 ) between the uveal melanoma groups. Compared to disomy 3 uveal melanomas, monosomy 3 tumors showed downregulation of HSP-27 and upregulation of vimentin ( Fig. 2 ; Table 4 ).
Expression of HSP-27 and Vimentin Protein in Sections of Uveal Melanoma
HSP-27 and vimentin protein expression were determined by immunohistochemistry in FFPE sections of an independent cohort of 41 uveal melanomas treated between 2006 and 2008, either by local resection or enucleation. Twenty-one of these tumors had been classified as disomy 3 and 20 as monosomy 3 after MLPA analysis of the corresponding diagnostic frozen tumor specimen. HSP-27 Immunoreactivity. The intrinsic positive control for HSP-27 in the enucleated eyes was the pigmented and nonpigmented ciliary body epithelium, which demonstrated cytoplasmic staining, whereas the intrinsic negative controls included macrophages and lymphocytes within the tumors. HSP-27 staining was also cytoplasmic in the uveal melanoma cells. The Mayer's hematoxylin counterstain facilitated assessment of the cellular morphology, and, therefore, determination of immunopositivity in either reactive or tumor cells. HSP-27 positivity ranged from 0% to 100% (mean, 64.0%) with tumor cells displaying various degrees of intensity between specimens ( Fig. 3A-D ; Table 5 ). HSP-27 staining also showed some intratumoral variation-for example, tending to be stronger in melanoma cells surrounding blood vessels and showing more heterogeneity in areas of epithelioid cells (Fig. 3) .
Vimentin Immunoreactivity. An intrinsic positive control for vimentin in the enucleated eyes was the retina, demonstrating positivity within the Müller cells and similar support cells. Vimentin staining was cytoplasmic and ranged from 10% to 100% (mean; 76.0%) within the tumor cells. As with HSP-27 staining, vimentin protein expression showed some intratumoral variation (Fig. 4) .
Correlation of HSP-27 and Vimentin Protein Expression with Clinicopathologic and Cytogenetic Risk Factors for Disease Progression and Metastasis
Clinicopathologic information for all patients included in this study is detailed in Table 5 . Briefly, these 41 patients with uveal melanoma had a mean age of 60.9 years (range, 34.0 -81.0) at primary treatment. All patients had been treated by enucleation or local resection (i.e., no uveal melanoma had undergone Statistical analysis of the HSP-27 protein expression score (i.e., percentage of tumor cells stained multiplied by intensity scores) was significantly lower in monosomy 3 uveal melanoma when compared with disomy 3 tumors (Student's t-test; P ϭ 0.011; Fig. 5A ). This remained statistically significant even if only the percentage of tumor cells stained was tested (Student's t-test; P ϭ 0.013; Fig. 5B ). Neither the vimentin protein expression score nor the percentage of tumor cells stained showed significant differences between monosomy 3 and disomy 3 tumors (Student's t-test; P ϭ 0.64 and P ϭ 0.60, respectively).
With respect to the histomorphologic features, statistical analysis of the HSP-27 protein expression score in uveal melanomas showed a negative correlation with mitotic frequency (Spearman's correlation; P ϭ 0.014). The vimentin protein expression score was significantly higher in uveal melanomas with closed loops than in those without (Student's t-test; P ϭ 0.011). In addition, a negative correlation was observed between the vimentin protein expression score and LBD (Spearman's correlation; P ϭ 0.043). Neither HSP-27 nor vimentin immunoreactivity showed a significant association with any other clinicopathologic variable tested (i.e., age of patient at primary diagnosis, cell type, or tumor height).
DISCUSSION
The present study demonstrates a statistically significant association between chromosome 3 loss in uveal melanomas and the downregulation of HSP-27 (P ϭ 0.011). This association was demonstrated with both proteomics and immunohistochemistry. To our knowledge, this correlation has not been reported previously. Our study raises the possibility of using immunohistochemical staining for HSP27 as a prognostic indicator when cytogenetic studies are not possible. HSPs are a class of functionally related proteins with expression that increases when cells are exposed to elevated temperatures or stress. Intracellular HSPs, including HSP-27 (located on chromosome 7), are overexpressed in a variety of cancer cells, are essential for the survival of these cell types, and have been demonstrated as being prognostically significant in some carcinomas. For example, HSP-27 overexpression is associated with a poor prognosis in gastric, prostate, and node-negative breast carcinomas. [17] [18] [19] In contrast, high levels of HSP-27 expression indicate a good prognosis in non-small-cell lung carcinomas and ovarian carcinomas. 20, 21 HSPs have been reported previously in a limited number of uveal melanomas and cell lines. 7, 9, 22 Pardo et al. 7 described several HSPs with the exception of HSP-27, in the proteome of a single patient with uveal melanoma. Zuidervaart et al. 9 reported relative HSP-27 overexpression in a cell line derived from a uveal melanoma metastasis compared with the cell line derived from the corresponding primary uveal melanoma. High levels of HSP-27 expression were also reported in 20 enucleated eyes with uveal melanoma. 22 As in our study, this investigation found variability in HSP-27 staining across the uveal melanomas, but did not find any correlation between HSP-27 expression and known histopathologic prognostic parameters. We did, however, find a negative correlation between HSP-27 and the mitotic rate of the uveal melanomas. This finding will be examined in more detail in a larger study.
Our finding of a decreased expression of HSP-27 in monosomy 3 uveal melanomas may be indirectly supported by recent studies on cutaneous melanoma. Of interest, in the human cutaneous melanoma cell line A375, 23 HSP-27 overexpression has been shown to inhibit cell proliferation and reduce cell invasiveness. Similarly, in a knockdown model of secreted protein acidic and rich in cysteines (SPARC) expression in cutaneous melanoma, 24 there is an increased HSP-27 expression, resulting in inhibited tumor progression. It could be postulated that underexpression of HSP-27 in melanoma cells results in increased tumor cell motility and invasiveness.
Vimentin, whose gene is located on chromosome 10, is a member of the intermediate filament family of proteins, which, along with microtubules and actin microfilaments, make up the cytoskeleton of cells. Vimentin is usually expressed in malignancies of mesenchymal cell origin (e.g., melanomas) and rarely, in those tumors arising from epithelium (e.g., carcinomas). Overexpression of vimentin intermediate filaments is associated with increased tumor invasiveness and migration in a variety of tumor types in vitro, [25] [26] [27] [28] because of its role in the process of epithelial-to-mesenchymal transition. There is a complex and dynamic relationship between EMT markers, such as vimentin, smooth-muscle actin and cadherins, as well as other proteins involved in extracellular matrix remodeling and invasion (e.g., SPARC and laminin). 29 Fuchs et al. 30 examined 52 uveal melanomas for vimentin expression, and correlated the findings with histomorphologic features and clinical course. 30 Similar to our present study, vimentin expression was found in all uveal melanomas studied, irrespective of cell type, with immunopositivity being demonstrated in more than 50% of the neoplastic cells. While Fuchs et al. could not demonstrate any relationship between vimentin expression levels and tumor size, cell type, pigmentation, or metastatic progression, we found a significantly higher vimentin expression in those uveal melanomas containing closed loops.
One of the main strengths of our study is that in the uveal melanomas examined immunohistochemically, chromosome 3 status was determined using MLPA, which was more sensitive and informative than FISH, providing data on 13 loci on chromosome 3. 4 The relatively low sensitivity of FISH in detecting partial deletions in chromosome 3 in uveal melanoma and in subdividing these tumors into high-and low-risk metastatic subtypes, has been reported by our group 2,4 and others. 31 Despite the statistical correlation between loss of chromosome 3 and HSP-27 underexpression shown in the present study, our data give only an approximate indication of the sensitivity and specificity with which HSP-27 expression predicts monosomy 3, because of the small number of tumors examined and the relatively short follow-up period. We are currently studying a larger cohort of patients, with longer follow-up. We are particularly interested in metastatic death occurring in patients with a disomy 3 uveal melanoma showing underexpression of HSP-27 protein.
In conclusion, our data suggest that low-to-negative HSP-27 protein expression levels in uveal melanoma are strongly associated with monosomy 3. Our preliminary results must be validated by larger studies to determine whether measurement of HSP-27 expression by immunohistochemistry can reliably predict survival when cytogenetic studies are not possible. Additional investigations are also needed to understand the functional significance of HSP-27 in uveal melanoma and its relationship to other proteins implicated in the process of epithelial-to-mesenchymal transition.
